“A Double-Masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease”, Ocul Immunol Inflamm, vol. 15, pp. 63-70, 2007.,
“Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration”, J Autoimmun, vol. 21, pp. 283-293, 2003.
“Infliximab for the Treatment of Active Scleritis”, Can J Ophthalmol, vol. 44, pp. e9-e12, 2009.,
“Subcutaneously administered daclizumab (SC-DAC, humanized anti-IL-2 receptor antibody) therapy for uveitis”, 2003.,